Cord Blood for Stem Cell Transplant Could Outperform Matched Sibling Donor

Cord blood transplantation may be the preferred donor source among patients able to tolerate more intensive conditioning regimens at high risk for a cancer relapse, reports a new study.

Cord blood as a source for bone marrow transplant could outperform even the accepted "gold standard" of matched sibling donor for cancer patients, reports a new study. The findings of the study are published in the journal Blood Advances.

When a cancer patient needs a bone marrow transplant, there are four common donor sources: A matched related donor (sibling), a matched unrelated donor (from a donor database), a half-matched donor, or umbilical cord blood.

Body's Own Immune System Linked to Cancer Relapse
Cancer relapse can happen weeks or years after the primary cancer was treated. This happens when the immune system loses its ability to keep cancer in check.

‘Umbilical cord blood is a well-established donor source for adult hematopoietic stem cell transplantation.’

Of course, there are plusses and minuses to each approach, but consensus has generally ranked a matched sibling first, followed by a matched unrelated donor, with cord blood and half-matched donors reserved for patients without either of the first two options.

Now a University of Colorado Cancer Center study based on a decade of research and treatment may reshuffle this list. In fact, the comparison of 190 patients receiving cord-blood transplants with 123 patients receiving transplants from the "gold standard" of matched sibling donors showed no difference in survival outcomes between these two approaches, with significantly fewer complications due to chronic graft-versus-host disease in patients receiving transplants from cord blood.

"Our cord blood patients were doing as well as patients receiving transplants from matched siblings, and in selected populations, cord blood patients were doing even better. Our program at CU Cancer Center is somewhat unique in its emphasis on cord blood as a donor source for stem cell transplants, and this study is an affirmation of why we do what we do here," says Jonathan Gutman, MD, CU Cancer Center investigator and director of the allogeneic stem cell transplantation program at UCHealth University of Colorado Hospital.

Epigenetic Drugs: A Hope to Reduce Cancer Relapse
Biology in high school taught us that we inherit certain traits from our parents that are pre-determined.

In addition to showing a decrease in the chance of graft-versus-host disease, which develops when a transplanted blood system attacks a patient’s tissues, the study shows a slightly lower rate of relapse in these patients undergoing transplant with cord blood.

"Especially with younger, fitter patients who we can hit harder in the transplant process, we have strong hints here that cord blood may be actively better in terms of reducing both graft-versus-host disease and relapse," Gutman says.

Cancer Relapse may be Reduced by 'Bed-of-Nails' Breast Implant
Implant materials that show promise in preventing breast cancer cells from dwelling and thriving have been developed by scientists.

Umbilical cord blood, which is banked for public use at designated centers around the world, is rich in stem cells, which can repopulate a patient’s blood system. Because these umbilical cord stem cells are more "basic" than adult blood cells, they require a lower degree of a match than blood cells from an adult donor. However, one challenge has been obtaining enough of these cells to perform a successful transplant.

"It turns out that for adults, it’s very hard to find a single cord blood unit that meets the parameters we know need to be met in terms of size. To overcome this barrier, we often use two units from different sources," Gutmans says. Also, research at CU Cancer Center and elsewhere are developing techniques to expand small samples of banked cord blood to the volume needed for transplant.

No Increase in Breast Cancer Relapse with Fat Graft Technique: Study
Exposure to autologous fat transfer does not increase the risk of breast cancer relapse in women.

"We think there are important advantages of cord blood, especially with respect to graft-versus-host disease," Gutman says. "Previously, we’ve taken a position recommending cord blood over matched unrelated donors, and now we show that cord blood may even out-compete the gold standard of matched sibling donors."

Source-Eurekalert